The novel class of GLP-1 receptor agonist and GIP dual medications, including tirzepatide, semaglutide, and the newly introduced retatrutide, provide promising advances in diabetes treatment . Despite https://researchpeptidesusa348362.bloggerszones.com/62078581/semaglutide-a-comparative-look